<DOC>
	<DOCNO>NCT02132624</DOCNO>
	<brief_summary>Chimeric antigen receptor ( CAR ) T cell target CD19 evaluate safety efficacy patient B cell lymphoma leukemia . The CAR consist CD19 target antibody scFv three intracellular signal domain derive CD3 zeta , CD28 4-1BB . Autologous T cell gene engineer CAR gene use retrovirus vector . Prior T cell infusion , patient subject precondition treatment . After T cell infusion , patient evaluate 24 month adverse reaction , persistence CAR T cell efficacy .</brief_summary>
	<brief_title>CD19-targeting 3rd Generation CAR T Cells Refractory B Cell Malignancy - Phase I/IIa Trial .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Relapsed refractory CD19+ Bcell lymphoma leukemia . Measurable disease . Performance status ECOG 02 . &gt; 18 year old . Fertile females/males must consent use contraceptive participation trial . Signed informed consent . Any significant medical psychiatric illness would prevent patient give informed consent follow study procedure . Patients primary CNS lymphoma . Known human immunodeficiency virus ( HIV ) infection . Active and/or severe infection ( e.g . tuberculosis , sepsis opportunistic infection , active hepatitis B virus ( HBV ) active hepatitis C virus ( HCV ) infection ) . Other serious underlie medical condition , , Investigator 's judgment , could impair ability patient . Treatment investigational product within 30 day prior enrollment , least 5 half life drug , long . Patients consent tissue blood sample store biobank . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>